Muscle, bone concerns with GLP‑1s
- A UNC review of 36 studies found muscle loss made up 25–40% of total weight loss in two‑thirds of semaglutide and tirzepatide users. (x.com) - Clinicians and experts are warning about potential bone‑health effects and offering strategies to protect bone density. (self.com) - Cosmetic effects such as facial volume loss are also prompting more patient conversations about trade‑offs. (dermatologytimes.com)
Glucagon-like peptide 1 drugs help people lose weight by slowing stomach emptying and increasing fullness, but some of that loss can come from muscle and bone-related tissue, not just fat. (healio.com) At the American College of Physicians meeting on April 17, University of North Carolina at Chapel Hill researcher John Batsis presented a review of 36 randomized trials of semaglutide, tirzepatide, liraglutide and dulaglutide. The median share of total weight loss tied to muscle-related measures was 34.9%, and 68% of studies exceeded a benchmark of about 25%. (healio.com) The review found the proportion was higher in studies of semaglutide and tirzepatide, the two drugs behind Wegovy, Ozempic, Zepbound and Mounjaro. Batsis said the trials did not measure objective physical function, so the review could not say how much the tissue loss changed strength or mobility. (healio.com) Doctors have watched this issue more closely as these medicines moved from diabetes care into obesity treatment after the Food and Drug Administration approved Wegovy for chronic weight management in June 2021. The current Wegovy label says semaglutide should be used with a reduced-calorie diet and increased physical activity. (dermatologytimes.com) (accessdata.fda.gov) Body-scan studies show why the debate is not simply about the number on a scale. In a STEP 1 substudy, semaglutide cut body weight by 15.0% over 68 weeks, with total fat mass down 19.3% and total lean body mass down 9.7%. (academic.oup.com) A SURMOUNT-1 substudy found tirzepatide reduced body weight by 21.3% over 72 weeks, with fat mass down 33.9% and lean mass down 10.9%. About 75% of the weight lost was fat mass and about 25% was lean mass in that analysis. (onlinelibrary.wiley.com) Bone is part of the concern because weight loss itself can lower bone density, and a 2025 review in *Osteoporosis International* said evidence in people with obesity is still limited but points to slight bone mineral density reduction and higher bone resorption with glucagon-like peptide 1 receptor agonists. The authors said fracture outcomes still need more study. (springer.com) One randomized trial in adults with increased fracture risk found semaglutide was linked to lower bone mineral density at the lumbar spine and total hip after 52 weeks, along with higher bone resorption than placebo. The study did not show an increase in bone formation markers. (thelancet.com) Researchers and clinicians are not arguing that the drugs should be abandoned. A 2024 comment in *Nature Reviews Endocrinology* said the key question is whether rapid weight loss from newer incretin drugs raises sarcopenia risk in susceptible patients, especially older adults. (nature.com) The trade-offs are also showing up in dermatology clinics, where fast fat loss in the face can make patients look older. *Dermatology Times* reported in January that Google searches for “Ozempic face” rose 4,600% from November 2021 to December 2024 as semaglutide prescribing climbed. (dermatologytimes.com) The practical message from the research is narrower than the hype: these drugs reduce fat, but they can also reduce lean tissue, and bone effects remain under study. That is why more obesity specialists are pairing prescriptions with resistance training, adequate protein and follow-up on body composition instead of weight alone. (accessdata.fda.gov) (springer.com)
